Unicycive Therapeutics is sued in a class action for allegedly failing to disclose unresolved FDA manufacturing deficiencies at a third-party vendor related to its kidney disease drug. The FDA issued a Complete Response Letter in June 2026, repeating concerns from the previous year, which caused Unicycive's stock to plunge 39%. Investors who bought shares between December 2025 and June 2026 may join the lawsuit. The case highlights risks in biotech regulatory approvals and potential delays impacting stock value.
General Electric (GE) announced it will acquire Consolidated Precision Products (CPP) for $11.75 billion to enhance its aerospace casting production. This strategic move aims to strengthen GE's manufacturing capabilities and accelerate engine technol...
Ionis Pharmaceuticals faced a setback when its experimental heart drug pelacarsen failed a Phase 3 trial to reduce cardiovascular events, causing an 8.6% stock drop. However, an analyst from Canaccord Genuity maintained a bullish $85 price target, im...
Casey's General Stores will release its Q3 2026 earnings on September 8 after market close, with analysts expecting an EPS of $6.78 and revenue of $5.56 billion. The company has a strong history of exceeding earnings estimates, with an average surpri...
Verisk Analytics introduced its new Verisk Fraud Discovery platform to enhance fraud prevention for insurers. Barclays adjusted the company's price target to $225, suggesting a 21.1% potential gain from the current stock price of $185.79. The company...
Adobe Inc. is undergoing a rare CEO transition with Anil Chakravarthy set to become CEO on December 1. Analyst opinions are divided: Oppenheimer rates Adobe as 'Perform' (hold), while Bank of America issues a 'Sell' rating with a $220 price target, c...
